BioTuesdays

Tag - Maxim Group

Medivir AB Logo
Markets

Maxim starts Medivir at buy; PT $3

Maxim Group initiated coverage of Sweden-based Medivir AB (OMX:MVIR-B) with a “buy” rating and $3 price target. The stock closed at 77 cents on June 16. Medivir is developing MIV-818 (fostrox), a prodrug of the...

June 17, 2022
Markets

Maxim starts Femasys at buy; PT $5

Maxim Group launched coverage of Femasys (NASDAQ:FEMY) with a “buy” rating and $5 price target. The stock closed at $1.30 on June 16. Femasys is developing treatments to address the two extremes of the women’s...

June 17, 2022
ABVC BioPharma Logo
Markets

Maxim starts ABVC BioPharma at buy; PT $3

Maxim Group initiated coverage of ABVC BioPharma (NASDAQ:ABVC) with a “buy” rating and price target of $3. The stock closed at 96 cents on June 16. ABVC is developing assets in ophthalmology, mental health, and oncology...

June 17, 2022
Virpax Pharmaceuticals
Markets

Maxim starts Virpax at buy; PT $4

Maxim Group initiated coverage of Virpax Pharmaceuticals (NASDAQ:VRPX) with a “buy” rating and price target of $4. The stock closed at $1.55 on June 8. Virpax is a diversified pre-clinical stage company developing non...

June 9, 2022
maxim Group Logo
Markets

Maxim reduces PTs in challenging biotech market

Maxim Group analyst Jason McCarthy, Ph.D., reduced price targets for 13 stocks in his coverage universe, citing macroeconomic winds and a significant decline in stock prices, particularly for small-cap biotech stocks...

May 26, 2022
Markets

Maxim starts Oncternal at buy; PT $3.50

Maxim Group initiated coverage of Oncternal Therapeutics (NASDAQ:ONCT) with a “buy” rating and price target of $3.50. The stock closed at 99 cents on May 9. Oncternal is a clinical-stage company focused on novel targets...

May 10, 2022
180-Life-Sciences
Markets

Maxim cuts 180 Life Sciences to hold; withdraws PT

Maxim Group downgraded 180 Life Sciences (NASDAQ:ATNF) to “hold” from “buy” and withdrew its price target, citing a financing overhang. The stock closed at $1.31 on May 6. Several weeks ago, 180 announced the...

May 9, 2022
Markets

Maxim starts Processa Pharma at buy; PT $9

Maxim Group initiated coverage of Processa Pharmaceuticals (NASDAQ:PCSA) with a “buy” rating and $9 price target. The stock closed at $2.87 on April 18. Processa is a clinical-stage company developing therapies for...

April 19, 2022
Synaptogenix
Markets

Maxim starts Synaptogenix at buy; PT $14

Maxim Group launched coverage of Synaptogenix (NASDAQ:SNPX) with a “buy” rating and price target of $14. The stock closed at $7.03 on April 11. Synaptogenix, formerly Neurotrope, is continuing development of bryostatin...

April 12, 2022